Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Adults
NCT04911790Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of coronavac in coronavirus disease 2019 (COVID-19), sponsored by Sinovac Biotech Ltd. Primary endpoint: Incidence of adverse reactions. Started Jun 2021; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04911790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911790.